Inhaled recombinant GM-CSF reduces the need for whole lung lavage and improves gas exchange in autoimmune pulmonary alveolar proteinosis patients
European Respiratory Journal · 2024-01 · 63 (1) · 2301233
DOI: 10.1183/13993003.01233-2023 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Respiratory Journal, online erschienen am 16.11.2023. Verfasst von Ilaria Campo und 13 weiteren Autor:innen. Beteiligte Einrichtung: Pneumology Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy. Hauptthemen laut MEDLINE: Pulmonary Alveolar Proteinosis, Autoimmune Diseases, Pulmonary Surfactants. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NHLBI NIH HHS, Agenzia Italiana del Farmaco, Ministero della Salute, National Heart, Lung, and Blood Institute.
Abstract (Originalsprache)
Rationale
Whole lung lavage (WLL) is a widely accepted palliative treatment for autoimmune pulmonary alveolar proteinosis (aPAP) but does not correct myeloid cell dysfunction or reverse the pathological accumulation of surfactant. In contrast, inhaled recombinant granulocyte–macrophage colony-stimulating factor (rGM-CSF) is a promising pharmacological approach that restores alveolar macrophage functions including surfactant clearance. Here, we evaluate WLL followed by inhaled rGM-CSF (sargramostim) as therapy of aPAP.
Methods
18 patients with moderate-to-severe aPAP were enrolled, received baseline WLL, were randomised into either the rGM-CSF group (receiving inhaled sargramostim) or control group (no scheduled therapy) and followed for 30 months after the baseline WLL. Outcome measures included additional unscheduled “rescue” WLL for disease progression, assessment of arterial blood gases, pulmonary function, computed tomography, health status, biomarkers and adverse events. Patients requiring rescue WLL were considered to have failed their assigned intervention group.
Results
The primary end-point of time to first rescue WLL was longer in rGM-CSF-treated patients than controls (30 versus 18 months, n=9 per group, p=0.0078). Seven control patients (78%) and only one rGM-CSF-treated patient (11%) required rescue WLL, demonstrating a 7-fold increase in relative risk (p=0.015). Compared to controls, rGM-CSF-treated patients also had greater improvement in peripheral arterial oxygen tension, alveolar–arterial oxygen tension difference, diffusing capacity of the lungs for carbon monoxide and aPAP biomarkers. One patient from each group withdrew for personal reasons. No serious adverse events were reported.
Conclusions
This long-term, prospective, randomised trial demonstrated inhaled sargramostim following WLL reduced the requirement for WLL, improved lung function and was safe in aPAP patients. WLL plus inhaled sargramostim may be useful as combined therapy for aPAP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Pneumology Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy.
- Translational Pulmonary Science Center, Cincinnati Children's Hospital, Cincinnati, OH, USA.
- Department of Pediatrics, University of Cincinnati, College of Medicine, Cincinnati, OH, USA.
- Clinical Epidemiology and Biometric Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
- Anesthesiology and Intensive Care Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
- Pediatric Clinic, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
ORCID-Profile: Ilaria Campo, Matthias Griese, Federica Meloni, Bruce C Trapnell
Förderung
- NHLBI NIH HHS
- Agenzia Italiana del Farmaco, Ministero della Salute
- National Heart, Lung, and Blood Institute
Zitieren
APA
Campo, I., Carey, B. C., Paracchini, E., Kadija, Z., De Silvestri, A., Rodi, G., De Amici, M., Torre, C., Zorzetto, M., Griese, M., Meloni, F., Corsico, A. G., Trapnell, B. C., & Mariani, F. (2024). Inhaled recombinant GM-CSF reduces the need for whole lung lavage and improves gas exchange in autoimmune pulmonary alveolar proteinosis patients. European Respiratory Journal, 63(1), 2301233. https://doi.org/10.1183/13993003.01233-2023
Vancouver
Campo I, Carey BC, Paracchini E, Kadija Z, De Silvestri A, Rodi G, et al. Inhaled recombinant GM-CSF reduces the need for whole lung lavage and improves gas exchange in autoimmune pulmonary alveolar proteinosis patients. European Respiratory Journal. 2024;63(1):2301233. doi:10.1183/13993003.01233-2023
BibTeX
@article{Campo2024,
author = {Campo, Ilaria and Carey, Brenna C and Paracchini, Elena and Kadija, Zamir and De Silvestri, Annalisa and Rodi, Giuseppe and De Amici, Mara and Torre, Cristina and Zorzetto, Michele and Griese, Matthias and Meloni, Federica and Corsico, Angelo Guido and Trapnell, Bruce C and Mariani, Francesca},
title = {Inhaled recombinant GM-CSF reduces the need for whole lung lavage and improves gas exchange in autoimmune pulmonary alveolar proteinosis patients},
journal = {European Respiratory Journal},
year = {2024},
volume = {63},
number = {1},
pages = {2301233},
doi = {10.1183/13993003.01233-2023}
}
EUVIMED